SIPS-2209-1

**SIPS-2209-1** is an oral fixed-dose combination tablet of the antidiabetic small molecules sitagliptin and pioglitazone. Sitagliptin inhibits dipeptidyl peptidase-4, increasing endogenous incretin activity and glucose-dependent insulin secretion, while pioglitazone activates peroxisome proliferator-activated receptor gamma to improve insulin sensitivity. Samik Pharmaceutical evaluated SIPS-2209-1 in a Phase 1 fasting-condition bioequivalence study in healthy Korean volunteers against concomitant administration of the individual-component products SIPS-2209-2 and SIPS-2209-3. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05787873))

Other names

pioglitazone + sitagliptinsitagliptin + pioglitazone